Shanghai RAAS Blood Products emphasizes the importance of safety, quality, and efficacy in its blood product offerings, which include albumin, immunoglobulins, and coagulation factors. The company has implemented rigorous quality control measures starting from the source plasma collection process, ensuring that plasma is sourced from healthy donors and adheres to strict regulatory standards. Notably, Shanghai RAAS is a pioneer in China for adopting advanced virus inactivation and examination methods, such as nucleic acid amplification, which significantly reduces the risk of blood-borne diseases and enhances product safety.

In addition to its commitment to product quality, Shanghai RAAS has established a robust infrastructure for plasma collection, operating 44 plasma donation centers across various provinces in China. This extensive network supports the company's operations and ensures a steady supply of source plasma for its products. The company’s focus on innovation is further highlighted by its collaboration with Boehringer-Ingelheim to develop new treatments for hemophilia, showcasing its dedication to advancing medical solutions in the blood products sector. Overall, Shanghai RAAS combines advanced technology with a strong commitment to safety and quality, positioning itself as a leader in the industry.

China

Shanghai RAAS Blood Products Co., Ltd. engages in the research, development, and manufacture of blood products and plasma-derived medical products.

2009 Wangyuan Road Fengxian District Shanghai, 201401 China

Shanghai Raas Blood Products

Company Details